An early report suggested that NFE2 could play a role in megakaryocyte transformation [35], and that knockdown of NFE2-related factor 2 (NRF2) in cervical cancer could enhance the efficacy of anticancer drugs [36]. This evidence concerns the gene NFE2 and cervical carcinoma.